RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Zhejiang Jiuzhou Pharma, an API company, will pay $16 million to acquire PharmAgra Labs of North Carolina, a small API CRO/CDMO business with contacts in the US and Europe. Jiuzhou makes APIs and it also provides CRO/CDMO services for APIs in China through its Rainbow Pharma division. In 2016, Jiuzhou formed a US JV with Frontage Labs to offer API and intermediate CDMO services. Earlier this month, Jiuzhou announced it would pay $110 million to acquire Novartis’s Suzhou API facility and supply APIs to Novartis. Source: China Biotoday
